Published in Am J Surg Pathol on February 01, 2006
Integrated genomic characterization of papillary thyroid carcinoma. Cell (2014) 6.05
MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab (2008) 3.40
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol (2008) 2.58
Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab (2013) 2.34
The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab (2013) 2.17
American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making. Thyroid (2015) 2.11
Morphology predicts BRAF (V⁶⁰⁰E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study. Virchows Arch (2014) 1.99
Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol (2009) 1.96
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol (2010) 1.70
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am (2008) 1.41
BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab (2012) 1.39
MicroRNAs in thyroid cancer. J Clin Endocrinol Metab (2011) 1.35
Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab (2008) 1.31
Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid (2010) 1.25
RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab (2013) 1.22
Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br J Cancer (2009) 1.21
A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer (2011) 1.21
Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res (2010) 1.21
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab (2007) 1.12
Targeting BRAF in thyroid cancer. Br J Cancer (2006) 1.08
Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid (2013) 1.02
Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. Hum Pathol (2015) 1.02
Evaluation of a thyroid nodule. Otolaryngol Clin North Am (2010) 1.01
BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients? World J Surg (2014) 1.00
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne) (2012) 1.00
Prognostic biomarkers in thyroid cancer. Virchows Arch (2014) 0.95
Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid (2010) 0.94
Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer (2014) 0.93
Herpes and polyoma family viruses in thyroid cancer. Oncol Lett (2016) 0.92
MicroRNA Role in Thyroid Cancer Development. J Thyroid Res (2011) 0.91
Thyroid cancer: current molecular perspectives. J Oncol (2010) 0.87
Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid (2013) 0.87
Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol (2016) 0.86
Current concepts and future directions in differentiated thyroid cancer. Clin Biochem Rev (2010) 0.85
Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol (2013) 0.85
Pax-8-PPAR-γ fusion protein in thyroid carcinoma. Nat Rev Endocrinol (2014) 0.85
TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch (2012) 0.85
Multi-targeted approach in the treatment of thyroid cancer. Minerva Chir (2010) 0.85
Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot. World J Surg (2008) 0.84
Evaluation of NDRG2 gene expression in primary papillary thyroid carcinoma and in metastases of this neoplasm to regional lymph nodes. Thyroid Res (2010) 0.84
Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features. Korean J Pathol (2014) 0.84
Prognostic factors of papillary and follicular carcinomas in Japan based on data of kuma hospital. J Thyroid Res (2011) 0.84
Preoperative RAS mutational analysis is of great value in predicting follicular variant of papillary thyroid carcinoma. Biomed Res Int (2015) 0.83
Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. Front Endocrinol (Lausanne) (2012) 0.83
Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET. Pediatr Surg Int (2008) 0.83
Autophagy in thyroid cancer: present knowledge and future perspectives. Front Endocrinol (Lausanne) (2015) 0.82
Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules. Otolaryngol Clin North Am (2014) 0.80
Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers. J Oncol (2010) 0.80
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol (2016) 0.78
BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. Mod Pathol (2015) 0.78
Targeted treatment of differentiated and medullary thyroid cancer. J Thyroid Res (2011) 0.77
Expression of X-linked inhibitor of apoptosis protein in neoplastic thyroid disorder. J Korean Med Sci (2011) 0.77
New insights into the diagnosis of nodular goiter. Thyroid Res (2014) 0.77
Identification of potential therapeutic targets for papillary thyroid carcinoma by bioinformatics analysis. Oncol Lett (2015) 0.77
A score based on microscopic criteria proposed for analysis of papillary carcinoma of the thyroid. Virchows Arch (2008) 0.76
Imaging mass spectrometry in papillary thyroid carcinoma for the identification and validation of biomarker proteins. J Korean Med Sci (2014) 0.76
β-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation. Oncotarget (2016) 0.75
Vanishing tumors of thyroid: histological variations after fine needle aspiration. Gland Surg (2016) 0.75
Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer. Dis Markers (2017) 0.75
Sonographic differences between conventional and follicular variant papillary thyroid carcinoma. Eur Arch Otorhinolaryngol (2017) 0.75
Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon. Hum Pathol (2017) 0.75
The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications. Curr Genomics (2017) 0.75
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med (2012) 7.06
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res (2003) 4.30
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab (2008) 3.40
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab (2009) 3.23
Upper-airway stimulation for obstructive sleep apnea. N Engl J Med (2014) 2.98
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest (2005) 2.77
Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol (2007) 2.75
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab (2003) 2.72
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol (2003) 2.67
Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol (2010) 2.55
Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell (2005) 2.47
Thyroid nodules (≥4 cm): can ultrasound and cytology reliably exclude cancer? World J Surg (2014) 2.40
Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab (2013) 2.34
Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biol Ther (2007) 2.32
MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol (2011) 2.25
Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res (2005) 2.23
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab (2013) 2.17
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett (2004) 2.00
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Molecular diagnostics and predictors in thyroid cancer. Thyroid (2009) 1.98
Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics (2005) 1.96
BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol (2012) 1.90
Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid (2009) 1.90
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology (2006) 1.85
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn (2008) 1.80
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery (2009) 1.72
PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol (2002) 1.70
A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid (2010) 1.68
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res (2002) 1.67
RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res (2002) 1.67
A randomized trial of temperature-controlled radiofrequency, continuous positive airway pressure, and placebo for obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg (2003) 1.65
Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules. J Clin Endocrinol Metab (2012) 1.60
Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res (2008) 1.58
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.56
Infarct-remodelled hearts with limited oxidative capacity boost fatty acid oxidation after conditioning against ischaemia/reperfusion injury. Cardiovasc Res (2012) 1.51
The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid (2009) 1.48
An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol (2009) 1.47
Adrenocortical carcinoma. Endocr Rev (2013) 1.46
Thyroid fine-needle aspiration: does case volume affect diagnostic yield and interpretation? Arch Otolaryngol Head Neck Surg (2011) 1.44
Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A (2005) 1.44
Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol (2004) 1.41
Recurrence after treatment of micropapillary thyroid cancer. Thyroid (2009) 1.41
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab (2006) 1.39
Multicenter study of a novel adjustable tongue-advancement device for obstructive sleep apnea. Otolaryngol Head Neck Surg (2010) 1.39
Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab (2008) 1.37
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36
American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid (2012) 1.36
Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res (2004) 1.35
Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol (2002) 1.33
RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab (2009) 1.32
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A (2014) 1.32
Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol (2013) 1.31
The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas (2004) 1.31
Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia (2006) 1.28
Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res (2005) 1.27
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res (2006) 1.27
MicroRNA expression profiles in thyroid tumors. Endocr Pathol (2009) 1.27
Polysomnography indexes are discordant with quality of life, symptoms, and reaction times in sleep apnea patients. Otolaryngol Head Neck Surg (2005) 1.26
Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res (2007) 1.26
Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab (2005) 1.24
Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab (2012) 1.24
Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol (2012) 1.23
Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2004) 1.23
Molecular analysis of thyroid tumors. Endocr Pathol (2011) 1.23
CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res (2010) 1.23